Invesco Ltd. Has $193.10 Million Stake in Solventum Co. (NYSE:SOLV)

Invesco Ltd. grew its position in Solventum Co. (NYSE:SOLV) by 6.4% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 2,923,119 shares of the company’s stock after purchasing an additional 176,201 shares during the quarter. Invesco Ltd. owned approximately 1.69% of Solventum worth $193,101,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of SOLV. New York Life Investment Management LLC grew its holdings in Solventum by 0.7% during the 4th quarter. New York Life Investment Management LLC now owns 18,506 shares of the company’s stock worth $1,223,000 after acquiring an additional 136 shares during the period. Blue Trust Inc. boosted its position in shares of Solventum by 2.1% during the 4th quarter. Blue Trust Inc. now owns 7,872 shares of the company’s stock valued at $549,000 after purchasing an additional 161 shares in the last quarter. MML Investors Services LLC grew its stake in Solventum by 3.2% during the third quarter. MML Investors Services LLC now owns 5,345 shares of the company’s stock worth $373,000 after purchasing an additional 168 shares during the period. Avantax Advisory Services Inc. increased its holdings in Solventum by 2.2% in the fourth quarter. Avantax Advisory Services Inc. now owns 8,835 shares of the company’s stock worth $584,000 after purchasing an additional 192 shares in the last quarter. Finally, EverSource Wealth Advisors LLC increased its holdings in Solventum by 48.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 687 shares of the company’s stock worth $45,000 after purchasing an additional 223 shares in the last quarter.

Solventum Trading Up 1.6 %

SOLV opened at $66.19 on Friday. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. The firm has a market capitalization of $11.45 billion and a PE ratio of 24.07. The company’s 50-day moving average is $74.19 and its 200 day moving average is $71.70. Solventum Co. has a fifty-two week low of $47.16 and a fifty-two week high of $85.92.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Piper Sandler raised their price objective on shares of Solventum from $75.00 to $84.00 and gave the stock a “neutral” rating in a research report on Friday, February 28th. Mizuho raised their price target on shares of Solventum from $70.00 to $82.00 and gave the stock a “neutral” rating in a report on Monday, March 3rd. Bank of America upped their price objective on shares of Solventum from $80.00 to $85.00 and gave the company a “neutral” rating in a report on Wednesday, February 26th. Wells Fargo & Company raised their target price on Solventum from $73.00 to $75.00 and gave the company an “equal weight” rating in a research note on Friday, February 28th. Finally, Morgan Stanley boosted their target price on Solventum from $73.00 to $80.00 and gave the company an “equal weight” rating in a research report on Wednesday, March 5th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $79.86.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.